[Antifibrinolytic therapy of subarachnoid hemorrhage. Permeation of oral paraaminomethylbenzoic acid in the cerebrospinal fluid].
Studies of the permeation of PAMBA in the cerebrospinal fluid of patients with intact or disturbed BBB function after oral administration of 6 g and withdrawal of the spinal fluid after 120 minutes exclusively showed concentrations which were below the identification threshold of the method using 1 micron per millilitre. Patients suffering from subarachnoidal haemorrhages mainly showed a permeation of PAMBA in the cerebrospinal fluid which, however, only rarely reached the lower therapeutically necessary concentration.
D010129:4-Aminobenzoic Acid / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D062365:Aminobenzoates / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects*; D013345:Subarachnoid Hemorrhage / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D062366:para-Aminobenzoates
D062365:Aminobenzoates; D000933:Antifibrinolytic Agents; D062366:para-Aminobenzoates; C015668:4-aminomethylbenzoic acid; D010129:4-Aminobenzoic Acid
Beitrag zur antifibrinolytischen Therapie bei Subarachnoidealblutungen. Untersuchungen über die Permeation der oral applizierten para-Amino-methylbenzoesäure in den Liquor.